Trichostatin A induces mesenchymal-like morphological change and gene expression but inhibits migration and colony formation in human cancer cells

Molecular Medicine Reports

Volumn 10, Issue 6, 2014, Pages 3211-3216

  Han, Rong Fei ^a   Li, Kai ^a   Yang, Zi Shan ^a   Chen, Zhi Guo ^a   Yang, Wan Cai ^a,b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cancer cells; EMT; Migration; TSA

Indexed keywords

BETA CATENIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR TWIST; TRICHOSTATIN A; TWIST1 PROTEIN, HUMAN; VIMENTIN;

BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HUMAN; MCF 7 CELL LINE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BETA CATENIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MCF-7 CELLS; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TWIST TRANSCRIPTION FACTOR; VIMENTIN;

EID: 84914164238     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.2594     Document Type: Article

References (22)

1. Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science 331: 1559-1564, 2011.
2. Sahai E: Illuminating the metastatic process. Nat Rev Cancer 7: 737-749, 2007.
3. Kang Y and Massagué J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118: 277-279, 2004.
4. Lu J, Guo H, Treekitkarnmongkol W, et al: 14-3-3ζ cooperates with ErbB2 to promote progression of ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 16: 195-207, 2009.
5. Mani SA, Guo W, Liao MJ, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715, 2008.
6. Buchwald M, Krämer OH and Heinzel T: HDACi - targets beyond chromatin. Cancer Lett 280: 160-167, 2009.
7. Acharya MR, Sparreboom A, Venitz J and Figg WD: Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68: 917-932, 2005.
8. Yoshikawa M, Hishikawa K, Marumo T and Fujita T: Inhibition of histone deacetylase activity suppresses epithelial-to-mesenchymal transition induced by TGF-beta1 in human renal epithelial cells. J Am Soc Nephrol 18: 58-65, 2007.
9. Bruzzese F, Leone A, Rocco M, et al: HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J Cell Physiol 226: 2378-2390, 2011.
10. Kong D, Ahmad A, Bao B, et al: Histone deacetylase inhibitors induce epithelial-to-mesenchymal transition in prostate cancer cells. PloS One 7: e45045, 2012.
11. Bolden JE, Peart MJ and Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784, 2006.
12. Scheel C, Eaton EN, Li SH, et al: Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell 145: 926-940, 2011.
13. Roth SY, Denu JM and Allis CD: Histone acetyltransferases. Annu Rev Biochem 70: 81-120, 2001.
14. Dokmanovic M, Clarke C and Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5: 981-989, 2007.
15. Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558, 2005.
16. Juan LJ, Shia WJ, Chen MH, et al: Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem 275: 20436-20443, 2000.
17. Ashburner BP, Westerheide SD and Baldwin AS Jr: The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21: 7065-7077, 2001.
18. Winer IS, Bommer GT, Gonik N and Fearon ER: Lysine residues Lys-19 and Lys-49 of beta-catenin regulate its levels and function in T cell factor transcriptional activation and neoplastic transformation. J Biol Chem 281: 26181-26187, 2006.
19. Li VS, Ng SS, Boersema PJ, et al: Wnt signaling through inhibition of beta-catenin degradation in an intact Axin1 complex. Cell 149: 1245-1256, 2012.
20. Li Y, Zhang X, Polakiewicz RD, et al: HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization. J Biol Chem 283: 12686-12690, 2008.
21. Mak AB, Nixon AM, Kittanakom S, et al: Regulation of CD133 by HDAC6 promotes β-catenin signaling to suppress cancer cell differentiation. Cell Rep 2: 951-963, 2012.
22. Bi X, Pohl N, Qian Z, et al: Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis 33: 326-330, 2012.